Go back

Nasdaq enters correction as Nvidia uncertainty and China curbs hit AI stocks

11m 49s

Nasdaq enters correction as Nvidia uncertainty and China curbs hit AI stocks

This Julius Baer Moving Markets podcast episode, hosted by Bernadette Anderko, covers a turbulent day in financial markets alongside a deeper discussion on China's rising role in biotechnology innovation. Lucia Ciacciolovic opens with market headlines, reporting that NVIDIA shares fell over 4% amid uncertainty about CEO leadership, pulling the Nasdaq down 2.5% into correction territory. The selloff was broad-based, hitting semiconductor stocks, server makers, software companies, and financials, while the VIX volatility index jumped nearly 20%. The Trump administration added further pressure by closing a loophole that allowed Chinese firms to rent NVIDIA's computing power through overseas data centers, a move described as a meaningful escalation. European markets largely weathered the storm, though the Stoxx 600 snapped a five-session winning streak, while healthcare offered a bright spot with Novo Nordisk gaining on positive weight-loss drug data. Bond yields eased as investors sought safety, the dollar strengthened past the 1.10 level against the euro, and commodities sold off broadly. In the second segment, Damien Ng from the Next Generation Research team discusses B1 Medicine, a Chinese biotech company that has hit a 52-week high and symbolizes China's shift from a healthcare market to a global source of biomedical innovation. China now accounts for roughly one-third of global pharma licensing value, making it deeply integrated into the global life sciences ecosystem. Ng acknowledges geopolitical tensions affecting the sector but notes that healthcare creates incentives for cooperation. Julius Baer maintains a constructive view on genomics, citing precision medicine, AI drug discovery, and aging populations as long-term drivers, while stressing the importance of selectivity amid regulatory and geopolitical volatility.

Transcription

1578 Words, 10099 Characters

English
Speaker 1Welcome to Julius Baer's Moving Markets podcast on Tuesday the 17th of November with me, Bernadette Anderko. We've talked about pharma companies offering immunotherapy treatments on the podcast before. Now B1, founded in China and previously known as Baijin, has recently hit a 52-week high and I'm going to be talking to Damien Ng from our Next Generation Research team today to discuss what this means for Chinese research and development capabilities in the field of genomics and of course the impact for investors. But that will be later in the podcast. First, I've got plenty of news to catch up on with my colleague Lucia Ciacciolovic. She's got all of the headlines from the last 24 hours in financial markets. Good morning to you, Lucia. Good morning, Bernadette. So another day, another twist in the NVIDIA saga. Yesterday there were some headlines about Jensen Huang possibly returning to the company. What's the latest there?
Speaker 2Yeah, investors certainly hope the board might bring him back, but sources say that is not happening. Treasury Secretary Scott Besant even urged the board to look outside the company for its next CEO over the weekend. Now, NVIDIA shares fell over 4% yesterday, dragging the whole market down. The Nasdaq dropped 2.5%, officially entering correction territory. The S&P 500 fell nearly 2% and the Dow fell 1.5%.
Speaker 1And this damage went far beyond just one chipmaker, right? I see the Philadelphia Semiconductor Index dropped over 5%.
Speaker 2Yeah, absolutely. It was a broad-based bettering. Intel and Micron fell over 7%. The storm spread to server makers like Dell, which fell 7%, and software giant Oracle, which dropped 5%. Now, eventually, the selling pressure spilled into financials, with JP Morgan and Goldman Sachs shedding around 2% to 3%. And the only safe harbors seem to be consumer defensives, which managed to stay afloat. Now, this market fear pushed the VIX volatility index up nearly 20% yesterday. It now stands at around 23 points this morning.
Speaker 1Staying with the topic of tech and artificial intelligence, are there any pivotal moments coming up for the trade?
Speaker 2Yeah, there are two big tests. So firstly, NVIDIA is reporting earnings today, and analysts expect nearly 100% year-over-year growth. But investors really want to know who will steer the ship next. And then secondly, AI firm Anthropic plans to price its IPO tomorrow on Wednesday. They are eyeing a valuation near $1.5 trillion, and it is a true test of investor
Speaker 1appetite. Yeah, it certainly will be. Meanwhile, Lucia, the Trump administration is adding fuel to the fire with new chip rules, right?
Speaker 2Yeah, exactly. The Commerce Department closed a loophole that let Chinese firms rent NVIDIA's computing power overseas. Analysts describe this as a meaningful escalation. It not only restricts physical chips, but also cuts off access through foreign data centers. This escalation rippled through Asia-Pacific markets overnight, with Taiwan and South Korea dropping over 2%. Shares in Japan and China were trading lower too.
Speaker 1All right, let's move to. Europe then. Were they shielded from the storm?
Speaker 2Mostly, Bernadette, though some cracks are showing. So European markets had enjoyed a five-session winning streak, but the Stock 600 snapped that streak, closing slightly lower yesterday. Tech names like ASML felt the pain. However, healthcare offered a bright spot. Novo Nordisk was higher after reporting very positive weight loss data for its Kagrisema drug. And on the macro front. Eurozone industrial production offered a nice surprise, swinging back into positive territory. And Switzerland also reported solid third quarter growth, defying expectations for a contraction.
Speaker 1All right, then why don't we turn to bonds, Lucia? Did they provide a safe haven yesterday?
Speaker 2Yeah, they did. U.S. Treasury yields eased as investors sought safety. The 10-year yield fell slightly to around 5.12%. However, rate hike expectations remain very much alive. Markets see a near certainty of a Fed rate hike in December. And Cleveland Fed President Beth Hammack said she prefers smaller increments, but left the door open for larger moves if they get behind the curve. Now, over in Europe, German 10-year bond yields briefly touched a three-and-a-half week high yesterday before setting slightly lower. UK two-year yield yields rose above 5% for the 10-year yield. That's right. The US dollar index
Speaker 1rose slightly to its highest level since last April.
Speaker 2The Euro-US dollar broke the psychologically important 1.10 level. And the greenback also gained against the British pound, the Aussie dollar and the Canadian dollar. Meanwhile, the dollar traded in a tight, tight range against the Japanese yen as yen-haven demand offset broad dollar strength with intervention concerns capping gains. In commodities, we saw a broad-based sell-off. Crude oil fell over 3% yesterday to around $86 a barrel. And it is trading at $85 this morning as signs of recovering flows through the Strait of Hormuz reinforced expectations of a surplus supply. Now, gold tumbled to a one-year low yesterday, but it is slightly up this morning. And copper also dropped to a four-month low yesterday, pressured by weak Chinese data and a stronger dollar.
Speaker 1OK, then finally, Lucia, looking ahead, what should investors be watching out for today?
Speaker 2We have some data releases on the agenda. We have just received the UK unemployment rate for September. And later this morning, we will get the German ZEW survey expectations for November, which will give us a fresh read on European economic sentiment. Then across the Atlantic, all eyes will be on the US economic calendar. We are awaiting October's retail sales and industrial production figures alongside the September business inventories numbers. And lastly, US stock futures were trading mixed with the S&P 500 in the red when I last checked. So let's see what today brings.
Speaker 1Indeed, we shall. Thank you very much for bringing us the latest markets news today, Lucia. Thank you for having me, Bernadette. Welcome to Biotechnology. Hello, Damien, and thanks for joining me today. So B1 Medicine's recent performance has attracted considerable attention. But beyond its share price gains, why is this company significant?
Speaker 3B1 Medicine matters because it symbolizes a broader transformation in China's biotechnology sector. A decade ago, many Chinese biopharma companies were primarily focused on manufacturing or serving domestic demand. Today, companies such as B1 are competing at the global innovation frontier. Its cancer therapy, Bupinza, has become a leading treatment category, what its international expansion demonstrates that Chinese firms are capable of discovering, developing, and commercializing innovative medicines on a global scale. In many ways, B1 is becoming an embodiment of China's transition from a healthcare market to a source of biomedical innovation. And how important,
Speaker 1therefore, has China become in global pharmaceutical innovation?
Speaker 3Good question, Bernadette. You know, China's role has grown dramatically. The country now accounts for roughly one-third of global pharma uplicensing value, highlighting increasing importance in drug discovery and development. This shift, in my opinion, is especially relevant for large pharma companies facing patent expiries and a need to replenish product pipelines. Many Western drug makers are looking to Chinese biotech firms for licensing deals, research partnerships, and access to innovative science. As a result, China has become deeply integrated into the global life sciences ecosystem, rather than operating on its periphery.
Speaker 1And a big subject for everyone at the moment, how does geopolitics affect the outlook for
Speaker 3biotechnology? Yeah, that's definitely one of the key questions, actually, in investing in biotech. You know, biotech is increasingly viewed as a strategic technology alongside artificial intelligence and semiconductors. Both the U.S. and China have introduced measures to protect critical technological capabilities. That creates uncertainty, particularly around areas such as biologics, cell therapies, and gene therapies. But biotech is somewhat unique because governments also recognize that biotech is a technology that can be used to protect critical capabilities. And biotech is a technology that can be used to protect critical capabilities. So, while geopolitical tensions may affect capital flows and certain cross-border investments, conventional licensing agreements and scientific collaboration are likely to remain important. So, healthcare often creates incentives for cooperation, even during periods of strategic competition. Well, I'm
Speaker 1sure you know what I'm going to ask you, Damian. What does this mean for investors? And why do you make this decision? Well, I'm sure you know what I'm going to ask maintain a constructive view on genomics.
Speaker 3Yeah, you know, Bernadette, we believe the long-term drivers remain intact. Advances in precision medicine, oncology, cell and gene therapies, and AI and AI drug discovery continue to expand what is scientifically possible. At the same time, aging populations and growing healthcare demand provide structured support for the sector. We acknowledge that geopolitical and regulatory developments may create periods of volatility, especially for some Chinese biotech companies. That is why selectivity remains important. Nevertheless, we maintain a constructive view on genomics because scientific progress and a medical need are likely to remain powerful drivers of innovation and growth over the coming decade.
Speaker 1Very interesting, Damian. It sounds like multiple. Multiple reasons to be involved, but choose wisely. Thanks very much for being on the podcast today.
Speaker 3Thank you very much, Bernadette.
Speaker 1Well, that concludes today's podcast. Thanks again to Lucia and Damian for joining me today and to you, of course, for listening. And please do tune in again tomorrow to catch up on what's moving markets then. I'm sure there'll be plenty to discuss after those all-important NVIDIA numbers. Meanwhile, good luck today and goodbye for now. Thank you.

Podcast Summary

Key Points:

  1. NVIDIA shares fell over 4% on leadership uncertainty, dragging the Nasdaq into correction territory with a 2.5% drop.
  2. The Philadelphia Semiconductor Index dropped over 5%, with Intel, Micron, Dell, and Oracle all suffering sharp declines.
  3. The Trump administration closed a loophole allowing Chinese firms to access NVIDIA computing power through overseas data centers, escalating tech tensions.
  4. European markets snapped a five-session winning streak, though healthcare offered a bright spot with Novo Nordisk rising on positive weight-loss drug data.
  5. U.S. Treasury yields eased as investors sought safety, but markets still expect a near-certain Fed rate hike in December.
  6. The dollar rose to its highest level since last April, breaking the psychologically important 1.10 level against the euro.
  7. B1 Medicine symbolizes China's transformation from a healthcare market into a global source of biomedical innovation, now accounting for roughly one-third of global pharma licensing value.
  8. Julius Baer maintains a constructive long-term view on genomics, citing precision medicine, AI drug discovery, and aging populations as key drivers, while emphasizing selectivity amid geopolitical volatility.

Summary:

This Julius Baer Moving Markets podcast episode, hosted by Bernadette Anderko, covers a turbulent day in financial markets alongside a deeper discussion on China's rising role in biotechnology innovation. 5% into correction territory. The selloff was broad-based, hitting semiconductor stocks, server makers, software companies, and financials, while the VIX volatility index jumped nearly 20%.

The Trump administration added further pressure by closing a loophole that allowed Chinese firms to rent NVIDIA's computing power through overseas data centers, a move described as a meaningful escalation. European markets largely weathered the storm, though the Stoxx 600 snapped a five-session winning streak, while healthcare offered a bright spot with Novo Nordisk gaining on positive weight-loss drug data. 10 level against the euro, and commodities sold off broadly.

In the second segment, Damien Ng from the Next Generation Research team discusses B1 Medicine, a Chinese biotech company that has hit a 52-week high and symbolizes China's shift from a healthcare market to a global source of biomedical innovation. China now accounts for roughly one-third of global pharma licensing value, making it deeply integrated into the global life sciences ecosystem. Ng acknowledges geopolitical tensions affecting the sector but notes that healthcare creates incentives for cooperation.

Julius Baer maintains a constructive view on genomics, citing precision medicine, AI drug discovery, and aging populations as long-term drivers, while stressing the importance of selectivity amid regulatory and geopolitical volatility.

FAQs

B1 Medicine symbolizes China's broader transformation in biotechnology from manufacturing and domestic demand to global innovation. Its cancer therapy Bupinza and international expansion show Chinese firms can discover, develop, and commercialize innovative medicines globally.

China now accounts for roughly one-third of global pharma licensing value. Many Western drug makers look to Chinese biotech firms for licensing deals, research partnerships, and access to innovative science.

Biotech is increasingly viewed as a strategic technology, creating uncertainty around areas like biologics, cell therapies, and gene therapies. However, licensing agreements and scientific collaboration are likely to remain important because healthcare creates incentives for cooperation.

Julius Baer maintains a constructive view on genomics, citing precision medicine, oncology, cell and gene therapies, and AI drug discovery as long-term drivers. Geopolitical and regulatory risks may cause volatility, so selectivity remains important.

NVIDIA shares fell over 4% amid uncertainty about its next CEO, dragging the Nasdaq into correction territory. The Philadelphia Semiconductor Index dropped over 5%, and selling spread to server makers, software, and financials.

NVIDIA reports earnings today, with analysts expecting nearly 100% year-over-year growth. AI firm Anthropic plans to price its IPO on Wednesday, eyeing a valuation near $1.5 trillion.

Chat with AI

Loading...

Pro features

Go deeper with this episode

Unlock creator-grade tools that turn any transcript into show notes and subtitle files.